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Abstract
Background
Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and 
local radiation selectively to cancer cells as well as the tumor microenvironment and thereby 
control cancer while minimizing toxicity. 
Design
In this review, we discuss the history, progress, and future potential of TαT in the treatment of 
prostate cancer, including dosimetry-individualized treatment planning, combinations with small-
molecule therapies, and conjugation to molecules directed against antigens expressed by 
prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of 
the tumor microenvironment.
Results
A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant 
prostate cancer has been demonstrated by radium-223 via improved overall survival and long-
term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and 
pharmacokinetic measurements of TαT provide the potential for optimization and individualized 
treatment planning for a precision medicine–based cancer management paradigm. The ability to 
combine TαTs with other agents, including chemotherapy, androgen receptor (AR)-targeting 
agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, 
TαTs that specifically target prostate cancer cells expressing PSMA represents a promising 
therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under 
investigation. 
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Conclusions
The described clinical benefit, safety and tolerability of radium-223 and the recent progress in 
TαT trial development suggest that TαT occupies an important new role in prostate cancer 
treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel 
approaches to combination therapies should expand the utility of TαT in prostate cancer 
treatment. 
Key Words
Targeted alpha therapy (TαT), radium-223, prostate cancer, prostate-specific membrane 
antigen (PSMA) 
Key Message
Targeted alpha therapy (TαT) delivers highly potent, selective, and local alpha radiation to 
cancer cells and the tumor microenvironment. TαT occupies an important place in prostate 
cancer treatment, and its utility may be expanded to multiple cancer types. This review 
discusses the history, progress, and potential of TαT in oncology with a focus on prostate 
cancer. 
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Introduction
The therapeutic effectiveness of specific radionuclides is determined by the specificity of 
targeting and the innate characteristics of the particle emitted, including potential range, 
effective travel distance in tissue, and the magnitude of energy emitted [1]. Radionuclides may 
be classified by their emission of particles, including alpha and beta particles [2]. Beta particles 
have a low linear energy transfer (LET) (0.2 keV/μm), which results in sparse ionization events, 
individual DNA lesions, and repairable single-strand DNA breaks. Alpha particles have higher 
LET (50–230 keV/μm), which results in clusters of double-strand breaks (DSBs) in DNA and 
increased cytotoxicity relative to beta particles. Alpha particles also have a shorter path length in 
tissue (50–100 μm) compared with beta particles (1000–10,000 μm). The short range of alpha 
particle radiation has the potential to minimize cytotoxic damage in non-targeted cells, 
potentially enabling specific cancer cell targeting with reduced toxicity to normal cells [3, 4]. This 
is exemplified by radium-223 dichloride (radium-223, Xofigo®), a first-in-class alpha particle–
emitting agent approved for castration-resistant prostate cancer (CRPC) with symptomatic bone 
metastases [5]. Radium-223 is a calcium mimetic that can preferentially bind to areas of 
hydroxyapatite deposition, such as bone metastases in prostate cancer (PC) [6-8]. Other bone-
seeking, beta particle–emitting radionuclides, such as strontium-89 and samarium-153-EDTMP, 
are indicated for pain relief for skeletal metastases [9-11]. Although these radionuclides 
provided pain palliation in bone-metastatic CRPC (mCRPC), they have failed to confer survival 
benefit [10, 12]. By contrast, in addition to reducing bone pain in a subset of patients, radium-
223 provided survival benefit when added to best standard of care (SoC) [7, 13, 14]. Recent 
progress in targeted alpha therapy (TαT) offers the potential to deliver cytotoxic radiation in a 
highly localized manner[3, 4]. In addition to exploring radium-223 in combination with other 
cytotoxic agents, androgen receptor (AR)-targeting agents, or immuno-oncology agents, 
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preclinical and clinical studies investigating other alpha particle–emitting radionuclides for use 
as TαTs (e.g. actinium-225 and thorium-227 conjugates) are ongoing (Table 1). This review will 
discuss the history, progress, and future potential of TαT for the treatment of PC, including: (1) 
treatment optimization and individualized planning; (2) combination therapies (e.g. radium-223 
with AR-targeting agents, cytotoxic agents, or immuno-oncology agents); (3) prostate-specific 
membrane antigen (PSMA) as an emerging therapeutic target; and (4) next-generation TαTs 
(e.g. targeted thorium-227 and actinium-225 conjugates).
What is the proof of concept for TαT?
Mechanism of action of radium-223, the first-in-class TαT in PC 
Radium-223 is the most-investigated TαT in clinical settings. Radium-223 is a calcium mimetic 
that is recruited to newly forming bone and induces an intense, local cytotoxic effect, affecting 
both cancer cells and the tumor microenvironment [8]. In murine tumor models, radium-223 
suppresses tumor-induced osteoblastic activity, tumor growth, and pathological bone formation 
[8]. In PC xenograft models, radium-223 inhibits abnormal bone metabolic activity by reducing 
the number of bone-forming osteoblasts and obliterating bone-degrading osteoclasts [8]. In vitro 
studies suggest that radium-223 may enhance T-cell–mediated lysis of prostate, breast, and 
lung carcinoma cells through induction of immunogenic cell death [15, 16].
Clinical outcomes of radium-223 treatment
Radium-223 has provided clinical proof of concept that TαT is an effective treatment strategy for 
PC [5]. In the phase III ALSYMPCA trial [17] of patients with bone-mCRPC and no known 
visceral metastases, radium-223 significantly extended overall survival (OS) (radium-223, 14.9 
months; placebo, 11.3 months; hazard ratio, 0.70 [95% CI, 0.58–0.83], P<0.001) [7]. Radium-
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223 also provided clinically meaningful improvement in health-related quality of life (QoL) and 
prolonged the time to first symptomatic skeletal event (SSE) and subsequent SSEs [7, 13]. 
Despite these results, median times to increase in prostate-specific antigen (PSA) levels were 
similar among treatment arms [7]. While rising PSA has been used as a biomarker for increased 
tumor growth, it has not been proven to be a reliable biomarker for therapies that do not directly 
affect the AR pathway [18, 19]. Potential biomarkers for treatment response with radium-223, 
including alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), are summarized in 
Table 2. Mutations in DNA repair pathway genes are included, as patients with these alterations 
may be particularly susceptible to radium-223 treatment [20-22] .
Combining radium-223 with second-generation AR-targeted therapies
Radium-223 has six years of real-world evidence supporting its efficacy and safety in mCRPC 
[7, 13, 14]. Because abiraterone and enzalutamide have both been shown to improve 
progression-free survival and OS as a first-line treatment for mCRPC, and neither has 
overlapping toxicity with radium-223, the combinations of these agents with radium-223 are 
being investigated [23, 24]. In a retrospective analysis of an international, early access, open-
label, single-arm, non-randomized trial including 696 patients with mCRPC, radium-223 used 
with initial and concurrent treatment with abiraterone or enzalutamide improved survival with no 
unexpected safety concerns [25]. In the eRADicAte study (NCT02097303), an investigator-
initiated, phase II, prospective, single-arm study including 31 patients with mCRPC, radium-223 
in combination with abiraterone plus prednisone (initiated <90 days prior to or <30 days after the 
first radium-223 treatment) conferred clinically meaningful improvements in QoL and pain, 
without unexpected adverse toxicities [26]. However, the phase III ERA 223 trial 
(NCT02043678) investigating radium-223 in concurrent combination with abiraterone plus 
prednisone/prednisolone raised safety concerns: more fractures (28.6% versus 11.4%, based 
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on central radiological review) were observed in the combination arm versus the arm with 
abiraterone plus prednisone/prednisolone alone [27, 28]. It should be noted that 79% of the 
fractures in the combination arm were not at sites of bone metastasis and osteoporotic fractures 
were most common [29]. The fact that the combination therapy in ERA 223 was administered 
concomitantly may partially explain the difference in safety profile compared with the 
ALSYMPCA, eRADicAte, and REASSURE studies. If the combination therapy was instead 
sequential, this may have allowed the bone to recover from the impact of the normal hormonal 
agent, thus preventing radium-223 from having a further compounding effect on bone 
irradiation. Additional analysis of the ERA 223 data showed a lower fracture rate in both study 
arms in patients who received bone health agents (BHAs) than in those who did not [29], 
suggesting that the use of BHAs could mitigate the risk of bone fractures for all patients. 
The US Food and Drug Administration evaluated the data of ERA 223 and added a warning 
statement on the use of radium-223 in combination with abiraterone acetate plus 
prednisone/prednisolone [5]. The Japanese Pharmaceuticals and Medical Devices Agency and 
Health Canada also issued a similar precaution [30, 31]. However, the European Medicines 
Agency (EMA) restricted the use of radium-223 to patients who have progressed following two 
prior systemic treatments for bone-mCRPC or who are ineligible for other treatments. The EMA 
also issued a contraindication for use in combination with abiraterone acetate plus 
prednisone/prednisolone [32]. Radium-223 is also being studied in combination with 
enzalutamide in ongoing phase II (NCT02225704) and phase III trials (NCT02194842) [33, 34]. 
The initial results of the phase III PEACE III (NCT02194842) trial show that, while fractures 
increased when radium-223 was added to enzalutamide, this risk was nearly abolished with 
continuous use of BHAs such as zoledronic acid [35]. After the trial was amended to make 
BHAs mandatory, no excess fractures were observed in the radium-223 arm [35].
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Can we personalize treatment and optimize clinical outcomes of TαT 
through the addition of dosimetry considerations?
Is TαT dosimetry feasible? 
One advantage of TαT compared with other systemic advanced PC modalities is that it enables 
collection of pharmacokinetic data by imaging in a clinical study setting, which can be used for 
dosimetry calculations [36]. Radiation dosimetry provides a logical basis for understanding the 
biological effects of radiation quantities and comparing the effects of different radiation-based 
treatments [37]. Owing to uptake heterogeneity of alpha particle emitters on a small scale and 
their potent cytotoxicity, macroscopic dosimetry at the tumor and organ levels is insufficient, and 
thus microdosimetry that takes into consideration the activity distribution as a function of time at 
the cellular and subcellular levels should be further developed for more-precise dosimetry 
calculations [37]. Currently, several small-scale modeling and microdosimetric approaches are 
being developed, with potential application to clinical imaging and dosimetry [36, 38-40].
Quantification of radium-223 uptake 
In vivo dosimetry requires in vivo radium-223 uptake quantification. The low gamma-radiation 
yield generated through the radium-223 decay pathway allows quantitative imaging of radium-
223 therapy and individualized biodistribution studies, although long image acquisition times 
limit the widespread use of this option [41-43]. 
Recent evidence has demonstrated a potential correlation between absorbed dose and local 
lesion response to TαT [42]. A study including nine patients with bone metastases reported that 
the lesion uptake quantification of radium-223 was significantly correlated with that of 
technetium-99m-methylene diphosphonate [43]. This introduces the possibility of using 
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conventional radiolabeled diphosphonate scintigraphy to contour bone lesions and define lesion 
extent in a more reliable manner.Overlapping radium-223 images of the region of interest allow 
for more accurate radium-223 uptake quantifications for dosimetry and for the assessment of 
local response of bone metastases to the therapy (i.e. lesion geometric extent and uptake) [43]. 
Dosimetry and clinical outcomes 
The feasibility of TαT dosimetry (e.g. in vivo quantification of radium-223 uptake [43]) might 
introduce the possibility of clinically investigating the value of personalized treatment and the 
outcome of radium-223 in relation to the absorbed dose. Recently, in a study including five 
patients with mCRPC, a correlation between fluorine-18-fluoride (18F-fluoride) and radium-223 
uptake was observed [42]. This study, to our knowledge, represents the first observed 
correlation between absorbed dose and local lesion response of TαT, suggesting that 
quantitative 18F-fluoride imaging might predict radium-223 uptake and, potentially, treatment 
response. More robust studies using more advanced imaging techniques are needed to confirm 
these preliminary findings, explore treatment optimization, and investigate the potential of 
dosimetry to predict clinical outcomes [42, 43]. 
In overall survival analyses of the number of radium-223 injections in patients with mCRPC in 
the US expanded access program, OS was longer in patients receiving 5 or 6 injections versus 
those receiving 1–4 injections [44]. However, a post hoc analysis of the ALSYMPCA trial 
showed similar findings with 5 or 6 injections of placebo versus 1–4 injections of placebo [45]. 
Further study is needed to determine the dosimetry of multiple cycles of radium-223 
incorporated in the bone, to assess its impact on biological activity and to investigate the 
potential of radium-223 dosimetry for treatment optimization and individualized treatment 
plans[41]. A randomized trial (NCT02023697) compared SSE-free survival (SSE-FS) with 
different radium-223 regimens in 391 patients with mCRPC and bone metastases: standard 
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activity (55 kBq/kg q4w for 6 cycles), high activity (88 kBq/kg q4w for up to 6 cycles), and 
extended standard activity (55 kBq/kg q4w for up to 12 cycles) [46]. No statistically significant 
differences in SSE-FS were observed between the standard activity and either the high or 
extended standard activity. However, an increased incidence of grade ≥3 treatment-emergent 
AEs were observed in the latter groups. This result supports the approved radium-223 regimen 
[46] and also supports the interest of dosimetry calculation to individualize the optimal activity 
regimen, as increased- or extended-activity regimens may not necessarily improve efficacy. 
The possibility of evaluating TαT distributions after injection and predicting absorbed radiation 
doses and exposure within tumor and normal tissues introduces the potential for optimizing 
treatment to maximize anti-tumor effect while sparing normal tissues [36]. 
What is the future of TαT in PC?
Radium-223–based radioimmunoconjugates were challenging to develop due to the difficulties 
associated with stable chelation and conjugation of radium-223 to biomolecules [47, 48]. 
However, combination of radium-223 with other treatments and at earlier disease stages may 
broaden its clinical utility [49]. For example, combination therapy of radium-223 with other anti-
tumor agents (e.g. chemotherapy, AR-targeting agents, DNA damage response [DDR] 
inhibitors, and immuno-oncology drugs) for PC may be a viable treatment approach. Clinical 
trials are ongoing to assess these combinations (Tables 1 and 3). Additionally, certain alpha 
emitters can be targeted to tumors by conjugating them to small molecules (e.g. actinium-225–
PSMA-617 and bismuth-213–PSMA-617) [50-52] or radioimmunotherapy, e.g. thorium-227 
conjugated to a monoclonal antibody [mAb]) that bind to specific antigens (e.g. PSMA) on tumor 
cells [3, 50]. Many preclinical and clinical studies are ongoing to investigate the potential of 
these therapeutic options, which may expand the utility of TαT in the management of PC.
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How to develop combination therapies which harness the MoA of TαT?
In addition to combining radium-223 with best SoC (e.g. local external-beam radiation therapy, 
corticosteroids, antiandrogens, estrogens, estramustine, or ketoconazole) [5], chemotherapy 
(e.g. docetaxel in the phase III DORA trial [NCT03574571] [53]) and other antiandrogens (e.g. 
enzalutamide in the phase III PEACE trial [34]), the MoA of radium-223 provides a basis for 
investigating its potential combination with other therapies, such as immuno-oncology agents 
and DDR inhibitors. 
Combining TαT with immuno-oncology agents 
In addition to cytotoxicity caused by the production of difficult-to-repair clusters of DNA DSBs 
(targeted effects), TαT may also produce off-target effects, such as systemic bystander 
(abscopal) effects that may be observed at distances from the target [3, 4, 37, 54, 55]. These 
systemic bystander effects are potentially mediated by the immune response [54] and could be 
exploited by appropriate treatment combinations. Combining alpha-emitted radiation and 
immunostimulatory therapies, such as anti-programmed death receptor-(ligand)1 (PD-1/PD-L1) 
or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) mAbs, has been shown to reduce 
nonirradiated metastatic tumor size and of metastatic spread [54]. However, randomized trials to 
confirm these preliminary findings are needed. Radium-223 has also been demonstrated to 
sensitize breast, prostate, and lung carcinoma cell lines to cytotoxic T-lymphocyte–mediated 
lysis by the induction of immunogenic cell death [15]. In in vitro cancer model systems, radium-
223 can increase expression of major histocompatibility complex-I, induce endoplasmic 
reticulum stress response in tumor cells, and upregulate the expression of calreticulin and 
induce its surface translocation. These events ultimately augment tumor sensitivity to T-
lymphocyte-mediated lysis [15]. The ability of TαT to induce immunogenic modulation and 
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enhance T-cell–mediated tumor cell lysis across multiple human tumor cell lines suggests wide-
ranging applicability and a potential for combination with immuno-oncology agents [15], such as 
atezolizumab [56], pembrolizumab [57], and sipuleucel-T [58].Given that TαT may modulate 
tumor phenotype and enhance T-cell lysis, it has been hypothesized that the immunostimulatory 
environment created by TαT may potentiate the anti-tumor activity of these immunotherapies 
[15]. Given the non-overlapping safety profiles of these therapies and their distinctive MoAs 
from radium-223, it is potentially advantageous to combine TαT and immuno-oncology agents. 
Currently, phase I trials examining the combination of atezolizumab and radium-223 are 
ongoing to investigate its potential in treating mCRPC with disease progression after androgen 
pathway inhibitor treatment (NCT02814669) [59], and in treating urothelial carcinoma with bone 
metastases and disease progression after platinum-based chemotherapy (NCT03208712) [60] 
(Table 3). NCT02814669 includes an adaptive study design with a cohort phase to evaluate the 
safety and tolerability of the combination with concurrent initiation or a staggered dosing 
(atezolizumab initiated at the beginning of cycle 2 or 3 of radium-223) before a potential 
randomization phase [59]. Pembrolizumab in combination with radium-223 is under investigation 
in a phase II trial in mCRPC (NCT03093428) [61]. Sipuleucel-T combined with radium-223 is 
being investigated in a phase II trial in men with asymptomatic or minimally symptomatic bone-
mCRPC (NCT02463799) [62] (Table 3). 
Combining TαT and DDR inhibitors 
DNA damage response (DDR) pathways comprise a network of signaling pathways that 
maintain genomic stability and cell viability by orchestrating the detection and repair of DNA 
damage with transient cell cycle arrest [63]. As mentioned above and shown in Table 2, several 
patients with alterations in DDR pathway genes have been shown to respond to radium-223 
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treatment [20-22]. Ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-
related protein (ATR) kinases are two master regulators of the DDR signaling pathway. ATM is 
primarily activated by double-strand breaks (DSBs), whereas ATR responds to a broad 
spectrum of DNA damage, including DSBs, lesions from interference with DNA replication, and 
elevated oncogene-induced replication stress [64, 65]. Poly (ADP-ribose) polymerase (PARP) 
also plays a vital role in DDR and can be activated by a wide range of stimuli (e.g. single-strand 
breaks, DSBs, and unusual DNA conformations) [66]. Defective PARP functions can lead to 
genomic instability and cell death, providing a basis for investigating PARP inhibitors (PARPis) 
in anti-cancer therapies [66]. It has been hypothesized that combining TαT and ATR inhibitors 
(ATRis) or PARPis may potentiate synthetic lethality and anti-tumor effects [49]. 
TαT and DDR inhibitor combination therapy has been explored in different tumor types [67]. For 
example, another TαT—thorium-227 conjugate targeting mesothelin, a surface glycoprotein 
overexpressed in multiple cancer types (e.g. pancreatic, ovarian, and lung cancers and 
mesothelioma) [68]—has demonstrated synergistic anti-tumor effects when combined with ATRi 
or PARPi in preclinical cancer models [67, 69]. These synergistic effects [67, 69] suggest that 
inhibiting DDR pathways may sensitize cancer cells to TαT and warrant clinical investigation. 
Currently, multiple clinical studies investigating the potential of combining TαT and DDR 
inhibitors in patients with mCRPC and bone metastases are ongoing, such as the phase Ib trial 
of radium-223 and the PARPi niraparib (NCT03076203) [70] and the phase I/II trial of radium-
223 and olaparib (NCT03317392) [71](Table 3).
PSMA — an emerging and promising target for PC therapy
PSMA is a type II transmembrane protein that is expressed at low levels in a variety of tissues 
(e.g. the prostate, brain, small intestine, salivary glands, and kidneys) and is overexpressed in 
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primary and metastatic PC cells [52, 72-75]. Although 5–10% of men with PC do not express 
PSMA, and PSMA may not be expressed uniformly within the tumor [76, 77], high levels of 
expression of PSMA are observed across the spectrum of aggressive and poorly differentiated 
PC [72-75, 78], making PSMA a promising therapeutic target [79]. PSMA targeting allows the 
creation of novel treatment options that would be complementary to existing therapies [80] 
(Figure 1). 
Investigational agents targeting PSMA can be labeled with different radionuclides, including 
alpha (e.g. actinium-225 and thorium-227) and beta emitters (e.g. lutetium-177 [177Lu] and 
iodine-131). These agents can be targeted to PSMA via different vehicles, such as antibodies 
(e.g. thorium-227–labeled anti-PSMA IgG1) and small-molecule ligands (e.g. 225Ac-PSMA-617). 
While antibodies bind PSMA with high affinity, they have a long serum half-life and greater 
potential for bone marrow and liver toxicity. Small-molecule ligands have a favorable 
biodistribution but have risk of off-target toxicity in the kidneys, salivary glands, and lacrimal 
glands [4, 52, 81]. Other PSMA-targeted therapies under investigation include vaccines and cell 
therapies. 
Among investigational PSMA-targeted therapeutics, beta particle–emitting radionuclides 
targeting PSMA include 177Lu-J591 and 177Lu-PSMA-617. Both agents demonstrated clinical 
activity in mCRPC [82-89]. A single-arm, single center, phase II study investigating 177Lu-PSMA-
617 in mCRPC found that 17 out of 30 patients with mCRPC achieved a ≥50% PSA decline, 
with a low toxicity profile and improvement in QoL [82]. A multicenter randomized phase II trial 
comparing 177Lu-PSMA-617 with cabazitaxel chemotherapy (NCT03392428) is ongoing [90]. 
The phase III VISION trial investigating PSMA-617 coupled to Lu-177 in mCRPC is also 
ongoing (NCT03511664) [91]. However, it seems some patients may not respond to 177Lu 
radioligand therapy, as 9 out of 30 patients saw no PSA response [ 92]. Such patients may 
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respond to an alpha particle–emitting radionuclide, such as actinium-225–PSMA-617 (225Ac-
PSMA-617) (Figure 2) [50]. Alpha particles are characterized by high LET and short travel 
distances; therefore, PSMA-targeted alpha therapies may cause potent and local cytotoxicity to 
PSMA-expressing cells [3, 4]. Alpha-labeled bisphosphonates, such as 225Ac-EDTMP or 225Ac-
zolendronate, may also be considered as they accumulate in the bone microenvironment of 
osteoblastic lesions [93, 94] .
What PSMA–TαT agents are under investigation for PC?
PSMA–TαTs under investigation 
Investigational TαTs targeting PSMA include bismuth-213–PSMA-617 (213Bi-PSMA-617) [51], 
225Ac-PSMA-617 [95], astatine-211–PSMA–pentanedioic acid (211At-PSMA-pentanedioic acid) 
[96], and thorium-227–labeled anti-PSMA IgG1 (227Th-PSMA-IgG1) [97]. The first-in-human 
treatment concept with 213Bi-PSMA-617 was demonstrated in a patient with mCRPC who had 
progressed on conventional therapy. Molecular imaging (re-staging with 68Ga-PSMA PET/CT) 
and biochemical (decline in PSA level from 237 μg/L to 43 μg/L) responses were observed in 
this patient after 11 months [51].
Initial clinical experience with targeted actinium conjugates 
225Ac-PSMA-617 was investigated in an observational, single-center study as salvage therapy 
among patients with mCRPC who had exhausted all approved treatment options and had a 
PSMA-positive tumor phenotype [50]. In the preliminary report including two patients who 
received ≥8 prior therapies, 225Ac-PSMA-617 (100 kBq/kg bimonthly) resulted in a PSA decline 
below the measurable level and complete imaging response in both cases [50]. In the full report 
including 14 patients, PSA response was observed in 75% of patients, and promising anti-tumor 
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activity was detected in brain, bone, liver, and pulmonary lesions. However, persistent 
xerostomia was regularly reported with a dose of 225Ac-PSMA-617 ≥100 kBq/kg per treatment 
cycle and was considered intolerable when the dose exceeded 150 kBq/kg. All-grade 
hematological AEs occurred in six patients (42.9%), and xerostomia was observed in eight 
patients (57.1%). With xerostomia being the dose-limiting factor, 100 kBq/kg was considered the 
maximum tolerable dose. Based on these findings, 100 kBq/kg 225Ac-PSMA-617 is tolerable and 
presents promising anti-tumor activity [95]. Antitumor activity of 225Ac-PSMA-617 was further 
demonstrated in 40 patients with mCRPC [98]. Although 225Ac-PSMA-617 was generally well 
tolerated, xerostomia remained the main reason for toxicity-associated treatment 
discontinuation [98]. Clinical trials with larger patient populations are needed to further 
investigate the efficacy, safety, and patient selection for 225Ac-PSMA-617. 
Preclinical development of targeted astatine and thorium conjugates 
211At-PSMA-pentanedioic acid has demonstrated significant tumor growth delay in a PC 
xenograft model. 211At-PSMA-pentanedioic acid also showed preclinical efficacy by significantly 
improving survival in mice bearing PC micrometastases. These results expand the potential 
utility of PSMA–TαTs from macrometastases to micrometastases of PC, including those not 
visible by traditional imaging techniques [96]. Another PSMA–TαT under preclinical investigation 
is 227Th-PSMA-IgG1, a targeted thorium conjugate delivering the alpha particle–emitting 
radionuclide thorium-227 to PC cells through a conjugated mAb (IgG1) specific for PSMA 
(Figure 3) [97]. 
Targeted thorium conjugates are next-generation TαTs that integrate a targeting molecule (e.g. 
mAb) stably bound to a chelator, and the alpha particle-emitting radioisotope thorium-227 
(227Th) [99-101] (Figure 3). Thorium-227 is a promising candidate for TαT for its relatively long 
half-life (18.7 days) and favorable chemical properties that allow stable chelation, preparation, 
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/advance-article-abstract/doi/10.1093/annonc/m
dz270/5550674 by C
hester Beatty R
esearch Institute user on 10 Septem
ber 2019
De Vincentis 18
and administration [101, 102]. In addition, thorium-227 decays via alpha particle emission to 
radium-223, which subsequently decays to stable lead-207; during this process, five alpha 
particles are released [102]. 
Preclinical studies showed that 227Th-PSMA-IgG1 was mainly distributed in tumors, followed by 
blood, with lower levels of distribution in other tissues (e.g. spleen, kidneys, and liver), indicating 
highly specific delivery of the alpha therapy to tumors. In vitro studies demonstrated that 227Th-
PSMA-IgG1 induced tumor cell death, difficult-to-repair DNA DSBs, and cell cycle arrest in 
G2/M phase of PC cells. 227Th-PSMA-IgG1 also induced immunogenic cell death of PC cells. 
These in vitro studies suggest that 227Th-PSMA-IgG1 may cause cytotoxicity through inducing 
DNA DSBs in PC cells and potentiation of tumor sensitivity to immunogenic lysis [97]. 
In vivo studies also demonstrated anti-tumor activity of 227Th-PSMA-IgG1 in several PC 
xenograft models (LNCaP-luc, C4-2, and LAPC-4) and its tolerability (i.e. no significant body 
weight loss). Tumor growth inhibition was observed with a single dose of 227Th-PSMA-IgG1 in 
both PC xenograft models with moderate (22Rv1) and high (MDA-PCa-2b) PSMA expression. 
In a bone-metastatic PC model, a single dose of 227Th-PSMA-IgG1 reduced tumor burden, 
abnormal osteoblastic bone growth, and serum PSA levels [97]. Potent dose-dependent 
antitumor activity of 227Th-PSMA-IgG1 was observed in both hormone-sensitive (ST1273) and 
enzalutamide-resistant (KuCap-1) patient-derived PC xenograft models [103]. 
Compelling preclinical evidence [97, 103] supports clinical investigation of 227Th-PSMA-IgG1 for 
PC, including mCRPC. Further development of other targeted thorium conjugates as precision 
anti-cancer modalities to deliver local alpha therapy to other tumor types are ongoing [104-106]. 
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Conclusions
TαT has the potential to deliver high-energy alpha radiation selectively to cancer cells and the 
tumor microenvironment in order to control cancer while minimizing systemic toxicity. The 
survival benefit and long-term safety profile of radium-223 demonstrated in clinical trials and 
clinical practice has provided both the proof of concept and real world experience for TαT as a 
viable therapeutic approach for cancer. Dosimetry calculation and pharmacokinetic 
measurements of TαT may drive precision medicine–based treatment in a more cost-effective 
and efficient manner. Potential combination of TαT with chemotherapy, AR-targeting agents, 
DDR inhibitors, or immuno-oncology drugs may enhance the anti-tumor activity of each 
individual therapy through synergistic or complementary interactions, which may expand the 
clinical utility of TαT in PC. Additionally, PSMA represents a promising therapeutic target for PC. 
PSMA-targeted thorium and actinium conjugates are under investigation as  next-generation, 
precision anticancer modalities that deliver local alpha therapy to PSMA-expressing cancer 
cells. 
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Figure Legends 
Figure 1. PSMA TαT is complementary to existing therapies for prostate cancer. Depicted is a 
suggested clinical sequencing, in which PSMA TαTs would be considered after a failure of a 
first-line therapy for mCRPC and PSMA expression was confirmed positive. ADT, androgen 
deprivation therapy; CT, computed tomography; mHSPC, metastatic hormone-sensitive 
prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; NAH, novel anti-
hormonal; nmCRPC, non-metastatic castration-resistant prostate cancer; PET, positron 
emission tomography; PSMA, prostate-specific membrane antigen; TAT, targeted alpha 
therapy.
Figure 2. PSMA as a potential therapeutic target for prostate cancer. PSMA is a 
transmembrane protein overexpressed in prostate cancer. The extracellular domain of PSMA is 
internalized after ligand binding, allowing intracellular delivery of conjugated therapeutic agents, 
such as actinium-225. PSMA, prostate-specific membrane antigen; TαT, targeted alpha 
therapy.
Figure 3. Schematic representation of 227Th-PSMA-IgG1. An N-hydroxysuccinimide-activated 
3,2-hydroxypyridinone chelator is coupled to the PSMA antibody and radiolabeled with the 
thorium-227 radionuclide. PSMA, prostate-specific membrane antigen.
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/advance-article-abstract/doi/10.1093/annonc/m
dz270/5550674 by C
hester Beatty R
esearch Institute user on 10 Septem
ber 2019
Table 1. TαTs in Prostate Cancer
 TαT MoA Half-life Number of 
alpha 
particles 
emitted 
Highlights of ongoing 
clinical trials or key 
findings
The phase III PEACE III trial 
on the combination of radium-
223 and enzalutamide in 
mCRPC [34]
The phase III DORA trial on 
the combination of radium-
223 and docetaxel in mCRPC 
[53]
Phase I trial on the 
combination of radium-223 
and atezolizumab in mCRPC 
[60]; phase II trials on 
pembrolizumab [61] or 
sipuleucel-T [62] and radium-
223 in mCRPC 
Radium-223 
dichloride
Bone-seeking 
alpha-emitting 
radionuclide [8]
11.4 
days 
[107]
4 [107]
Phase Ib trial of radium-223 
and niraparib (PARPi) in 
CRPC [70]; phase I/II trial of 
radium-223 and olaparib 
(PARPi) in mCRPC [71]
213Bi-PSMA-
617
45.6 
minutes 
[108] 
1 [108] Molecular imaging and 
biochemical responses in a 
patient with mCRPC [51]
225Ac-PSMA-
617
10.0 
days 
[109]
4 [109] Anti-tumor activity was 
observed in patients with 
mCRPC with xerostomia as 
dosing-limiting factor and 
reason of treatment 
discontinuation [50, 95, 98]
211At-PSMA-
pentanedioic 
acid
PSMA-targeting 
small-molecule 
ligand conjugated 
with alpha-
emitting 
radionuclide
7.2 hours 
[110]
1 [110] Significant tumor growth 
delay and improved survival 
were seen in preclinical 
prostate cancer xenograft 
model and mice bearing 
prostate cancer 
micrometastases [96]
227Th-PSMA-
IgG1
PSMA-targeting 
mAb conjugated 
with alpha-
emitting 
radionuclide
18.7 
days 
[102]
5 [102] Preclinical anti-tumor activity 
and safety were observed in 
models of prostate cancer 
[97, 103]; phase I trial of 
227Th-PSMA immune-
conjugate in mCRPC [111]
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CRPC, castration-resistant prostate cancer; DSB, double-strand breaks; mAb, monoclonal 
antibody; mCRPC, metastatic CRPC; MoA, mechanism of action; PARPi, poly (ADP-ribose) 
polymerase inhibitor; PSA, prostate-specific antigen; PSMA, prostate-specific membrane 
antigen; TαT, targeted alpha therapy
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Table 2. Summary of Potential Biomarkers for Treatment Response with Radium-223
Potential 
biomarker
Rationale Clinical evidence
Alkaline 
phosphatase 
(ALP)
ALP is a nonspecific 
marker of osteoblast 
activity [112] 
Patients treated with radium-223 
experienced significantly prolonged time to 
increase in tALP and a greater tALP 
response compared with placebo [7] 
tALP decline at 12 weeks after radium-223 
was initiated correlated with longer OS, but 
did not meet statistical surrogacy 
requirements [113]
Lactate 
dehydrogenase 
(LDH)
LDH is a metabolic 
enzyme that 
participates in the 
glycolysis and 
gluconeogenesis 
pathways, important 
for tumor growth [114, 
115]
LDH decline at 12 weeks after radium-223 
was initiated correlated with longer OS, but 
did not meet statistical surrogacy 
requirements [113]
Increased levels of LDH are associated 
with poor clinical outcomes in prostate 
cancer and aggressive phenotypes in 
patients with bone metastases [115]
CHEK2 (DNA 
repair gene)
Mutation corresponds to a higher risk of 
prostate cancer, but there is no clear 
familiar association [116] 
More than one patient who responded to 
radium-223 was found to have a mutation 
in this gene [20, 21]
BRCA2 (DNA 
repair gene)
Mutation corresponds to a higher risk of 
prostate cancer, with a familiar association 
[117] 
More than one patient who responded to 
radium-223 was found to have a mutation 
in this gene [20, 22] 
MRE11A (DNA 
repair gene)
A patient who responded to radium-223 
was found to have a mutation in this gene 
[20] 
CHD1 (DNA 
repair gene)
Loss of CHD1 in prostate cancer results in 
increased sensitivity to DNA damaging 
agents [118] 
A patient who responded to radium-223 
was found to have a mutation in this gene 
[20] 
SPOP (DNA 
repair gene)
Radium-223 emits 
alpha particles, which 
have high LET, 
resulting in clusters of 
DSBs in DNA. 
Therefore, patients 
with mCRPC with 
alterations in their 
DNA repair pathway 
genes may be 
particularly 
susceptible to radium-
223 treatment [20-22]
The most commonly mutated gene in 
primary prostate cancer that serves to 
modulate DNA DSB repair [119]
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A patient who responded to radium-223 
was found to have a mutation in this gene 
[20] 
tALP, total alkaline phosphate; OS, overall survival; CRPC, castration-resistant prostate cancer; 
mCRPC, metastatic CRPC; LET, light energy transfer; DSB, double-strand break
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Table 3. Clinical Trials Investigating Combination Therapies of TαT and Immuno-
oncology Agents or DDR Inhibitors
Agents in 
combination with 
TαT
Therapeutic 
indication
Phase ClinicalTrials.gov identifier
Immuno-oncology agents in combination with radium-223
Atezolizumab (PD-L1 
mAb)
mCRPC with 
disease progression 
after androgen 
pathway inhibitor 
treatment
I NCT02814669 [59]
Atezolizumab (PD-L1 
mAb)
Urothelial carcinoma 
with bone 
metastases and 
disease progression 
after platinum-based 
chemotherapy
I NCT03208712 [60]
Pembrolizumab (PD-1 
receptor mAb)
mCRPC II NCT03093428 [61]
Sipuleucel-T 
(autologous cellular 
immunotherapy 
Targeting PAP)
asymptomatic or 
minimally 
symptomatic bone-
metastatic CRPC
II NCT02463799 [62]
DDR inhibitors in combination with radium-223
Niraparib (PARPi) Bone-metastatic 
CRPC
Ib NCT03076203 [70]
Olaparib (PARPi) Bone-metastatic 
CRPC
I/II NCT03317392 [71]
ATRi, ataxia telangiectasia and Rad3-related protein inhibitor; CRPC, castration-resistant 
prostate cancer; DDR, DNA damage response; PAP, prostatic acid phosphatase; PARPi, poly 
(ADP-ribose) polymerase inhibitor; mAb, monoclonal antibody; mCRPC, metastatic CRPC; 
TαT, targeted alpha therapy
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 Figure 1. PSMA TαT is complementary to existing therapies for prostate cancer. Depicted is a suggested 
clinical sequencing, in which PSMA TαTs would be considered after a failure of a first-line therapy for mCRPC 
and PSMA expression was confirmed positive. ADT, androgen deprivation therapy; CT, computed 
tomography; mHSPC, metastatic hormone-sensitive prostate cancer; mCRPC, metastatic castration-resistant 
prostate cancer; NAH, novel anti-hormonal; nmCRPC, non-metastatic castration-resistant prostate cancer; 
PET, positron emission tomography; PSMA, prostate-specific membrane antigen; TAT, targeted alpha 
therapy. 
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 Figure 2. PSMA as a potential therapeutic target for prostate cancer. PSMA is a transmembrane protein 
overexpressed in prostate cancer. The extracellular domain of PSMA is internalized after ligand binding, 
allowing intracellular delivery of conjugated therapeutic agents, such as actinium-225. PSMA, prostate-
specific membrane antigen; TαT, targeted alpha therapy. 
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 Figure 3. Schematic representation of 227Th-PSMA-IgG1. An N-hydroxysuccinimide-activated 3,2-
hydroxypyridinone chelator is coupled to the PSMA antibody and radiolabeled with the thorium-227 
radionuclide. PSMA, prostate-specific membrane antigen. 
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